Sarepta Therapeutics (SRPT) Gets a Buy Rating from Credit Suisse


Credit Suisse analyst Martin Auster maintained a Buy rating on Sarepta Therapeutics (SRPT) yesterday and set a price target of $189. The company’s shares closed yesterday at $111.99.

According to TipRanks.com, Auster is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -12.6% and a 15.4% success rate. Auster covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings Inc, Alexion Pharmaceuticals, and Intellia Therapeutics.

Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $197.11, a 76.0% upside from current levels. In a report issued on November 6, Citigroup also maintained a Buy rating on the stock with a $188 price target.

.

See today’s analyst top recommended stocks >>

Based on Sarepta Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $76.39 million. In comparison, last year the company had a GAAP net loss of $47.73 million.

Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is neutral on the stock. Earlier this month, Hans Lennart Rudolf Wigzell, a Director at SRPT sold 6,667 shares for a total of $936,714.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts